Loading…
Loading…
iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 6,747 shares, a growth of 428.3% from the December 31st total of 1,277 shares. Approximately 0.1% of the shares of
The iShares Genomics Immunology and Healthcare ETF is invested in 49 companies involved in genomics, immunology and bioengineering. Compared with the biotechnology benchmark IBB, IDNA has value characteristics, but has greatly underperformed, losing over 20% since its inception. Among genomics-focused ETFs, PBE offers a relatively safer choice with better performance and lower volatility.
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.
This article provides a monthly dashboard with aggregate industry metrics in the healthcare sector. Fast facts on IDNA, a thematic and volatile biotech ETF. We conclude with 10 healthcare stocks cheaper than their peers in February.
To use a holiday analogy, I have been checking lists and checking them twice to figure out which of next year's top disruptive investment themes are likely to be nice.
Good Morning, VettaFi Voices! Disruptive innovation is a popular topic, and it encompasses everything from bitcoin and cryptocurrency to electric vehicles to artificial intelligence.
I rate IDNA a Hold due to its focus on biotech stocks with long-term growth potential in a rapidly growing healthcare industry. Despite impressive growth since its inception in 2019, IDNA has experienced a downward trajectory since 2021, with its current price lower than at inception. The healthcare industry is predicted to be the fastest growing industry in the US in 2023, with a 15% growth rate expected by 2027, making it a profitable long-term investment space.
Genomic revolution and pharmacogenomics have strong growth prospects that may enable the iShares Genomics Immunology and Healthcare ETF biotech portfolio to generate supernormal growth. In order to enable retail investors to benefit from this technological advancement in the field of DNA, investors can think of options like IDNA. Since its creation, IDNA's price has more than doubled within a span of almost 39 months. However, since September 2022, price has been in a steady decline.